Economic burden of tyrosine kinase inhibitor (TKI) treatment failure in patients with chronic myeloid leukemia (CML).

被引：0
|
作者：
Chen, Yaozhu J.
Huang, Hui
Divino, Victoria
Pokras, Shibani
Hallinan, Shawn
Munakata, Julie
Taylor, Catherine
McGarry, Lisa
Ng, Daniel
Nieset, Christopher
Knopf, Kevin B.
机构：
[1] IMS Hlth, Alexandria, VA USA
[2] ARIAD Pharmaceut Inc, Cambridge, MA USA
[3] IMS Hlth, San Francisco, CA USA
[4] ARIAD, Cambridge, MA USA
[5] Calif Pacific Med Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.7091
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7091
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
    Haznedaroglu, Ibrahim C.
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2014, 6 (01)
  • [2] Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy
    Barber, Mary C.
    Mauro, Michael J.
    Moslehi, Javid
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 110 - 114
  • [3] Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence
    Ciftciler, R.
    Haznedaroglu, I. C.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (24) : 7787 - 7798
  • [4] Supporting Adherence to Tyrosine Kinase Inhibitor (TKI) Therapy Among Patients with Chronic Myeloid Leukemia (CML)
    Nodzon, Lisa
    Tinsley-Vance, Sara
    BLOOD, 2017, 130
  • [5] Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia
    McGarry, Lisa J.
    Chen, Yaozhu J.
    Divino, Victoria
    Pokras, Shibani
    Taylor, Catherine R.
    Munakata, Julie
    Nieset, Christopher C.
    Huang, Hui
    Jabbour, Elias
    Malone, Daniel C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (02) : 289 - 299
  • [6] Tyrosine kinase inhibitors (TKI): a new revolution in the treatment of chronic myeloid leukemia (CML)
    Aviles-Vazquez, Socrates
    Chavez-Gonzalez, Antonieta
    Mayani, Hector
    GACETA MEDICA DE MEXICO, 2013, 149 (06): : 646 - 654
  • [7] A Role for Lipid Metabolism in Tyrosine Kinase Inhibitor (TKI) Resistance of Chronic Myeloid Leukemia (CML)
    Gonzalez, Mayra A.
    Lopez, Jose L.
    Schenkel, Katherine
    Reffell, Kelaiah
    A.Eide, Christopher
    Bajpeyi, Sudip
    M.Eiring, Anna
    BLOOD, 2021, 138
  • [8] Caring for Patients with Chronic Myeloid Leukemia (CML) Receiving Tyrosine Kinase Inhibitor (TKI) Therapy in an Era of Evolving Treatment Goals
    Nodzon, Lisa A.
    Tinsley, Sara M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S224 - S225
  • [9] Subcutaneous Omacetaxine (OM) Treatment of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients Following Multiple Tyrosine Kinase Inhibitor (TKI) Failure.
    Cortes, Jorge E.
    Wetzler, Meir
    Lipton, Jeff
    Nicolini, Franck E.
    Baccarani, Michele
    Baer, Maria R.
    Khoury, H. Jean
    Cram, David
    Humphriss, Eric D.
    Benichou, Annie-Claude
    Craig, Adam
    Kantarjian, Hagop M.
    BLOOD, 2010, 116 (21) : 944 - 944
  • [10] An Ethnographic Investigation Tracking the Experience of Chronic Myeloid Leukemia (CML) Patients on Tyrosine Kinase Inhibitor (TKI) Therapies
    Guilhot, Francois
    Coombs, John
    Szczudlo, Tomasz
    Zernovak, Oleg
    Macdonald, Nancy J.
    Shapiro, Ari
    BLOOD, 2010, 116 (21) : 176 - 177
12345